Welcome to our dedicated page for Cartesian SEC filings (Ticker: RNAC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cartesian Therapeutics, Inc. (NASDAQ: RNAC) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Cartesian describes itself as a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, with lead CAR-T programs Descartes-08 and Descartes-15. Its SEC filings offer detailed information on clinical development, financial position, governance and risk factors that complement the company’s press releases.
Investors researching RNAC can use this page to review current and historical Forms 10-K and 10-Q for audited and interim financial statements, discussion of operations, and disclosures about the Descartes-08 and Descartes-15 programs. Form 8-K filings provide timely updates on material events, such as clinical data announcements, trial initiations or pauses, changes in development priorities, financial results releases, board appointments and executive transitions, amendments to bylaws, and updates to the company’s code of business conduct and ethics.
Cartesian’s filings also document equity awards and inducement grants, board and committee roles, and other compensation arrangements, which can be relevant for understanding governance and incentive structures. Where applicable, proxy materials describe director elections and governance policies, and registration statements outline the terms of any registered offerings.
Stock Titan enhances these RNAC filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly identify important disclosures related to Descartes-08’s Phase 3 AURORA trial in myasthenia gravis, expansion into myositis and pediatric indications, and the status of Descartes-15. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, and 10-Ks appear promptly, while Form 4 insider transaction reports can be reviewed to see equity transactions by directors and officers as disclosed to the SEC.
By combining original SEC documents with AI-generated explanations, this page helps users interpret Cartesian Therapeutics’ regulatory reporting, understand how clinical and strategic developments are reflected in official filings, and follow the evolution of RNAC as a clinical-stage biotechnology issuer.
Cartesian Therapeutics, Inc. insider reporting shows a trust-related conversion of preferred stock into common stock. On April 2, 2026, Seven One Eight Three Four Irrevocable Trust elected to convert a portion of its Series A Non-Voting Convertible Preferred Stock into 758,001 shares of common stock at a stated conversion price of $0.0000 per share, all held indirectly with Elizabeth Hoge acting as trustee.
Following the conversion, the Trust holds 5,313,261 shares of common stock and 33,662.224 shares of Series A Non-Voting Convertible Preferred Stock, with the remaining preferred shares subject to a beneficial ownership limitation. A separate indirect holding reflects 506,999 shares of common stock held by Hoge's spouse. Footnotes state these securities stem from merger consideration and a private placement completed in November 2023.
Cartesian Therapeutics, Inc. insider filing shows a trust converting preferred stock into common shares. On April 2, 2026, a trust for the benefit of Murat Kalayoglu’s spouse and children exercised 22,740.03 shares of Series A Non-Voting Convertible Preferred Stock to acquire 758,001 shares of common stock at a conversion price of $0.00 per share.
After the transaction, the trust held 33,662.224 shares of the preferred stock and 5,313,261 shares of common stock indirectly. Murat Kalayoglu also held 506,999 shares of common stock directly. The filing reflects a derivative exercise and conversion, not an open-market purchase or sale.
An investor group led by Murat Kalayoglu updated its ownership in Cartesian Therapeutics, Inc. common stock. The group now reports beneficial ownership of 5,833,971 shares, about 19.9% of the company’s common stock, based on 28,544,728 shares outstanding as of March 31, 2026.
On March 31, 2026, Murat Kalayoglu resigned from the board of directors. On April 2, 2026, a trust affiliated with him converted 22,740.030 shares of Series A Preferred Stock into 758,001 shares of common stock, contributing to the currently reported ownership levels across the reporting persons.
Cartesian Therapeutics, Inc. reported that board member Murat Kalayoglu, M.D., Ph.D. has informed the company he will resign from its Board of Directors, effective March 31, 2026, to pursue other opportunities.
He currently serves as Chairman of the Board’s Science and Technology Committee and as a member of the Nominating and Corporate Governance Committee, and will cease serving on these committees in connection with his resignation. The company states that his decision was not due to any disagreement with the company regarding its operations, policies, or practices and expresses appreciation for his service since 2023.
Cartesian Therapeutics director Michael Singer reported a bona fide gift of 6,555 shares of Common Stock on March 13, 2026. The gift was made at no stated price and is classified as a non-market disposition rather than a sale.
After the gift, Singer directly holds 49,578 shares. He also reports additional indirect holdings in Cartesian Therapeutics through several trusts, a spouse account, and custodial accounts for his children under UTMA.
Cartesian Therapeutics, Inc. disclosure: multiple Squarepoint entities report beneficial ownership stakes in Common Stock totaling between 30,949 and 2,209,601 shares per entity as filed on 03/09/2026.
The filing lists Squarepoint Ops LLC, Squarepoint Capital LLP, Squarepoint Operations Private Limited, and Squarepoint (DIFC) Ltd each holding 2,209,601 shares (reported 8.34% of the class), Squarepoint Master Fund Limited holding 2,178,652 shares (8.22%), and Squarepoint Core Master Fund Limited holding 30,949 shares (0.12%).
Cartesian Therapeutics, Inc. outlines its business as a late clinical-stage biotechnology company developing mRNA-engineered cell therapies for autoimmune diseases, led by Descartes-08.
Descartes-08, an autologous anti-BCMA mRNA CAR-T, is being advanced for generalized myasthenia gravis, myositis and juvenile dermatomyositis. It has Orphan Drug and RMAT designations for myasthenia gravis and Rare Pediatric Disease Designation for juvenile dermatomyositis. Phase 1/2 myasthenia gravis studies showed deep, durable symptom improvements over 12 months without observed cytokine release syndrome or neurotoxicity, supporting outpatient dosing without preconditioning chemotherapy.
The company has initiated a Phase 3 AURORA trial in acetylcholine receptor antibody–positive myasthenia gravis under a Special Protocol Assessment and is preparing randomized trials in myositis and a pediatric basket trial. Development of Descartes-08 in systemic lupus erythematosus and of next-generation CAR-T Descartes-15 in multiple myeloma has been paused to prioritize autoimmune indications. Cartesian highlights in-house cGMP manufacturing capacity in Frederick, Maryland, a growing global patent estate extending into the 2040s, and key license agreements with Biogen, the U.S. National Cancer Institute and Sobi.
Cartesian Therapeutics, Inc. reported full year 2025 results and a business update centered on its Descartes-08 cell therapy pipeline. The company ended December 31, 2025 with approximately $126.9 million in cash, cash equivalents and restricted cash, which it expects to fund planned operations into mid-2027, including completion of the Phase 3 AURORA trial.
Total 2025 revenue was $2.8 million, down from $38.9 million in 2024, reflecting much lower collaboration and license revenue. Research and development expenses rose to $58.0 million and general and administrative expenses to $31.5 million. An impairment charge of $56.7 million contributed to a larger net loss of $130.3 million, or $5.02 per basic share, compared with a $77.4 million loss in 2024.
Clinically, enrollment is progressing in the Phase 3 AURORA trial in myasthenia gravis, which plans to enroll about 100 patients and was highlighted by Nature Medicine as a trial to watch in 2026. A Phase 2 TRITON trial in myositis is expected to start in the first half of 2026, while the Phase 1/2 HELIOS pediatric trial in juvenile dermatomyositis is actively enrolling. Descartes-08 has received multiple U.S. FDA designations, and recent Nature Medicine publications described its mechanism of action and 12‑month response data. Leadership changes included adding cell therapy veteran Adrian Bot, M.D., Ph.D., to the board and appointing CEO Carsten Brunn, Ph.D., as chairman.
FMR LLC has filed Amendment No. 3 to a Schedule 13G reporting its beneficial ownership of 1,366,989 shares of Cartesian Therapeutics Inc. common stock, representing 5.3% of the class as of December 31, 2025. FMR reports sole voting power over 1,366,854 shares and sole dispositive power over 1,366,989 shares. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over the same 1,366,989 shares and no voting power, reflecting her control position in FMR. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Cartesian Therapeutics.
An insider of RNAC, identified as Christopher M. Jewell, filed a Rule 144 notice to sell 9,000 shares of common stock. The planned sale is to be executed through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value listed as $68,940.00 and total shares outstanding shown as 26,003,606. The shares to be sold were acquired on 01/10/2025 by exercising options under a registered plan for cash. Over the prior three months, the same seller reported additional common stock sales of 17,935 shares on 11/19/2025 for $129,587.55 and 10,510 shares on 01/09/2026 for $84,256.57, indicating ongoing liquidation of a portion of their position.